In November 2023, we opened a new clinical unit in Ostrava (CZ). We have now received all necessary certificates for operation (including European GCP), and client audits are currently underway.

In addition, preparations for the first studies are progressing well, and we estimate that very first study will be initiated by the second quarter of this year.

To remind you of the festive atmosphere of the ribbon-cutting ceremony, we have prepared a video of the opening speech below.

The speech was held by Stephan Holl, CEO of Conscio Group, Roman Grunt, CEO of Quinta – Analytica, Jiří Juchelka, PI of Quinta – Analytica, and in the name of cooperation by Cyril Kučera, Deputy for Medical Care of the Ostrava City Hospital.

Additional News

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.

ALL POSTS